药物信息为Clindamycin Phosphate and Benzoyl Peroxide (Mylan Pharmaceuticals Inc.): CLINICAL PHARMACOLOGY
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- CLINICAL STUDIES
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED AND COMPOUNDING INSTRUCTIONS
- 外部链接相关的Clindamycin Phosphate and Benzoyl Peroxide (Mylan Pharmaceuticals Inc.)
An in vitro percutaneous penetration study comparing ClindamycinPhosphate and Benzoyl Peroxide Gel, 1%/5% and topical 1% clindamycin gel alone, demonstrated there was no statistical difference in penetration between the two drugs. Mean systemic bioavailability of topical clindamycin in ClindamycinPhosphate and Benzoyl Peroxide Gel, 1%/5% is suggested to be less than 1%.
Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. Less than 2% of the dose enters systemic circulation as benzoic acid. It is suggested that the lipophilic nature of benzoyl peroxide acts to concentrate the compound into the lipid-rich sebaceous follicle.
Microbiology
The clindamycin and benzoyl peroxide components individually have been shown to have in vitro activity against Propionibacterium acnes an organism which has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes was not examined in clinical trials with this product.
- Drug Information Provided by National Library of Medicine (NLM).
